Tempus AI (TEM) Expected to Release Quarterly Earnings on Thursday

Tempus AI (NASDAQ:TEM) is projected to announce its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Tempus AI to announce earnings of ($0.13) per share and revenue of $379.6680 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. The firm had revenue of $348.12 million during the quarter, compared to analyst estimates of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The business’s revenue for the quarter was up 36.1% on a year-over-year basis. During the same period last year, the company earned ($0.24) earnings per share. On average, analysts expect Tempus AI to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tempus AI Price Performance

Shares of TEM traded down $0.59 during mid-day trading on Tuesday, reaching $42.31. 3,038,228 shares of the stock traded hands, compared to its average volume of 5,855,282. The company has a market cap of $7.60 billion, a price-to-earnings ratio of -24.73 and a beta of 3.46. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. The firm has a fifty day moving average price of $51.63 and a 200 day moving average price of $53.30. Tempus AI has a 1 year low of $40.77 and a 1 year high of $104.32.

Wall Street Analyst Weigh In

Several research firms recently commented on TEM. BTIG Research reaffirmed a “buy” rating and set a $80.00 target price on shares of Tempus AI in a report on Monday, June 1st. Freedom Capital raised shares of Tempus AI to a “hold” rating in a research report on Tuesday, June 30th. Lake Street Capital lowered Tempus AI to a “hold” rating in a research report on Monday, July 20th. Wall Street Zen raised shares of Tempus AI from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Jefferies Financial Group assumed coverage on Tempus AI in a research note on Monday, April 13th. They issued an “underperform” rating and a $35.00 price target on the stock. Nine research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $68.92.

Insiders Place Their Bets

In other news, CFO James William Rogers sold 11,529 shares of Tempus AI stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $55.00, for a total transaction of $634,095.00. Following the completion of the sale, the chief financial officer directly owned 114,866 shares in the company, valued at approximately $6,317,630. This trade represents a 9.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Polovin sold 8,703 shares of the stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $383,541.21. Following the transaction, the executive vice president owned 128,215 shares in the company, valued at approximately $5,650,435.05. The trade was a 6.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 449,793 shares of company stock valued at $23,248,231. Insiders own 24.26% of the company’s stock.

Institutional Trading of Tempus AI

Several hedge funds have recently modified their holdings of TEM. ARK Investment Management LLC boosted its stake in Tempus AI by 5.3% in the fourth quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock valued at $446,275,000 after acquiring an additional 381,816 shares in the last quarter. State Street Corp boosted its position in Tempus AI by 9.8% in the fourth quarter. State Street Corp now owns 1,616,338 shares of the company’s stock valued at $95,445,000 after buying an additional 143,676 shares during the last quarter. Voloridge Investment Management LLC increased its stake in shares of Tempus AI by 183.0% in the third quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock worth $129,708,000 after acquiring an additional 1,039,176 shares during the period. Franklin Resources Inc. increased its stake in shares of Tempus AI by 0.4% in the third quarter. Franklin Resources Inc. now owns 1,456,120 shares of the company’s stock worth $117,523,000 after acquiring an additional 5,375 shares during the period. Finally, AQR Capital Management LLC raised its holdings in shares of Tempus AI by 6.4% during the third quarter. AQR Capital Management LLC now owns 904,872 shares of the company’s stock worth $73,032,000 after purchasing an additional 54,692 shares during the last quarter. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.